Search clinical trials for: Early access program

Total 31566 results

Alnylam Pharmaceuticals

Approved for marketing

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria

Belgium
Beni-Suef University

Completed

Early Detection of Children With Developmental Disabilities in Assiut Governorate

Autism Spectrum Disorder | Down Syndrome | Developmental Disability | Development Delay | Motor Delay

Egypt
Gilead Sciences

No longer available

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Mario Negri Institute for Pharmacological Research

Withdrawn

COVID-19 Algorithm Treatment at Home (COVER-HOME)

COVID-19
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Cook MyoSite

Available

Expanded Access Program for Autologous Muscle Derived Cells (AMDCs) (AMDC)

United States
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Novartis Pharmaceuticals

Available

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals

Available

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals

Available

Lamprene Multiple Patient Program

Non-Tuberculous Mycobacterial (NTM) Infections

United States, Canada
Novartis Pharmaceuticals

Available

MAP to Provide Access to Eltrombopag, for Treatment of Patients With Medically Significant Thrombocytopenia

Thrombocytopenia
Novartis Pharmaceuticals

Available

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Melanoma
Novartis Pharmaceuticals

Available

CTL019 Out of Specification MAP for ALL or DLBCL Patients

Acute Lymphoblastic Leukemia (ALL) | Diffuse Large B-cell Lymphoma (DLBCL)

United States, Canada, Australia
Novartis Pharmaceuticals

Available

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

Sickle Cell Disease
Novartis Pharmaceuticals

Available

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Small Cell Lung Carcinoma
Novartis Pharmaceuticals

Available

Managed Access Programs for LDK378, Ceritinib

Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
Novartis Pharmaceuticals

Available

Managed Access Programs for LNP023, Iptacopan

Paroxysmal Nocturnal Hemoglobinuria (PNH) | C3 Glomerulopathy (C3G)
Oregon Health and Science University
Providence Health & Services

Active, not recruiting

Autism ALERT Expansion

Autism Spectrum Disorder

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)

Pulmonary Hypertension

United States, Spain, Australia, United Kingdom, Canada, Belgium, Argentina, Israel, Japan, Philippines, Germany, Mexico, Brazil, Czechia, Netherlands
Day One Biopharmaceuticals, Inc.

Available

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Low-grade Glioma
Mayo Clinic

Completed

Increasing Digital Equity and Access Among Rural Patients (IDEA) Study

Smoking Cessation

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Carcinoma, Renal Cell

United States, Australia, Canada, Chile, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
UCB Biopharma SRL

No longer available

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Early Detection of Lung Cancer

Lung Cancer

United States
Marinus Pharmaceuticals

No longer available

Ganaxolone Expanded Access Program Compassionate Use (CDD)

CDKL5 Disorder
Aydin Adnan Menderes University

Completed

Effect Of Early Intervention Program Applied To Premature Infants

Nursing Caries | Infant Development | Premature Infant Disease | Patient Comfort

Turkey
Novartis Pharmaceuticals

Completed

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Chronic Myeloid Leukemia With T315I Mutation

Switzerland
Boehringer Ingelheim

Completed

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

China
Vanderbilt University Medical Center
Veloxis Pharmaceuticals

Enrolling by invitation

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Lung Transplant; Complications

United States
Boston Children's Hospital

Completed

PEWS Implementation in an LMIC Setting (PEWSPAL)

Oncology

Palestinian Territory, occupied
Medical University of Vienna
University of Valencia; Anglia Ruskin University; Servicio Madrileño de Salud... and other collaborators

Completed

Cancer Prevention and Early Detection Among the Homeless Population: The Health Navigator Model (CANCERLESS)

Cancer

Spain, Austria, Greece, United Kingdom
Children's Hospital Los Angeles
National Center for Advancing Translational Sciences (NCATS); AltaMed Health...

Suspended

The Impact of Parent Training on the Child's Health Services

Parenting | Child Behavior Problem | Child Rearing

United States
Harvard School of Public Health (HSPH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

An Intervention to Improve Antenatal Access to CD4 Testing and HAART in Botswana

HIV Infection | Pregnancy

Botswana
Memorial Healthcare System
Harvard Medical School (HMS and HSDM); University of Miami; Vanderbilt University...

Completed

Coaching Program to Address Burnout, Wellness and Professional Development in Early Career Pediatric Surgeons

Burnout, Professional | Well-Being, Psychological | Surgical Residents

United States
Takeda

Available

Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)
Harvard School of Public Health (HSPH)
Conrad N. Hilton Foundation; ChildFund Kenya; B&M Consult

Active, not recruiting

Evaluation of a Group-based Parenting Intervention for Early Childhood Development

Child Development

Kenya
NSABP Foundation Inc
National Cancer Institute (NCI); Radiation Therapy Oncology Group

Active, not recruiting

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Stage II Breast Cancer | Stage IB Breast Cancer

United States, Canada, Israel, Puerto Rico, Korea, Republic of, Japan, Ireland
Lawson Health Research Institute
Sunnybrook Health Sciences Centre; Weill Medical College of Cornell University and other collaborators

Active, not recruiting

Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy (SIGNAL 2)

Early Stage Breast Carcinoma

Canada
Bristol-Myers Squibb
AbbVie

No longer available

Early Patient Access Treatment Use Protocol CA204-220

Multiple Myeloma

Japan
Cairo University

Completed

Effect of Early Coma Arousal Therapy on Conscious Level Recovery and Cognition in Traumatic Brain Injury

Traumatic Brain Injury With Loss of Consciousness

Egypt
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Parkinsons Disease

United States, United Kingdom, Canada, France, Luxembourg, Poland, Spain, Italy, Austria
Ludwig-Maximilians - University of Munich
European Union

Active, not recruiting

European Childhood Obesity Project: Early Programming by Infant Nutrition? (CHOP)

Infant Development

Belgium, Germany, Italy, Poland, Spain
Massachusetts General Hospital
Massachusetts Department of Health

Enrolling by invitation

Evaluating the Effectiveness of a Drug Education and Diversion Program for Middle and High School Students (iDECIDE)

Substance Use | Health Risk Behaviors | Adolescent Behavior | Youth

United States
Western University, Canada
Iowa State University

Completed

Early Prevention of Excessive Gestational Weight Gain Using Lifestyle Change (NELIP)

Birth Weight | Excessive Weight Gain in Pregnancy With Baby Delivered | Excessive Weight Gain in Pregnancy, First Trimester

Canada
Janssen Scientific Affairs, LLC

Available

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma
Foundation for Innovative New Diagnostics, Switzerland
Indian Council of Medical Research; University of Oxford; WHO, Special Programme...

Completed

Advancing Access to Diagnostic Innovation Essential for UHC and AMR Prevention (Accelerator)

Acute Febrile Illness

Uganda, Burkina Faso, Ghana, India, Nepal
Wake Forest University Health Sciences

Completed

Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers (ACCESS)

Gastrointestinal Cancer

United States
University of Sao Paulo
Harvard School of Public Health (HSPH)

Completed

Home Visiting Programs to Improve Early Childhood Development and Maternal Mental Health

Mental Health Wellness 1 | Child Development

Search clinical trials for: Early access program

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations